Abstract
Background to investigate endometrial carcinoma prognostic value of some histopathological and immunohistochemical factors, fairly easily accessible in every routinely pathology lab set.
Methods we considered patients affected by endometrial carcinoma with available clinical and radiological follow-up data after radical hysterectomy (S. Martino Polyclinic Hospital, Genoa, Italy, period 1/1/2013 - 1/7/2016). We analyzed the following histopathological items: histotype, stage (FIGO), type of infiltration (infiltrative/espansive), desmoplasia, intratumoral necrosis, tumor infiltrating lymphocytes and lymph vascular spaces invasion. Moreover, each case has been investigated with a panel of immunohistochemistry including estrogen receptor α, progesteron receptor, Ki67, p53, β-catenin, e-cadherin, bcl-2 and cyclin D1. Primary endpoints were disease free survival and overall survival.
Results out of 99 cases eligible for our purpose, we found 69 low-grade endometrioid, 8 high-grade endometrioid and 22 other high-grade endometrial carcinomas. Disease free survival multivariate analysis showed a strong significant correlation between poor prognosis and advanced stage (p=0.0042). Advanced stage (p=0.0003) and presence of desmoplasia (p=0.04) resulted significantly correlated to a worse prognosis in overall survival multivariate analysis. In univariate model, the non-endometrioid histotype was significantly correlated with an unfavorable prognosis when compared to the endometriod type. Same for progesteron receptor low expression.
Conclusion the multivariate analysis confirmed the central prognostic role of stage in endometrial carcinoma. Moreover, other immunohistochemical markers in univariate analysis, have confirmed their easily reproducible usefulness, well integrating the recent TGCA molecular classification.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Retrospective Study
Funding Statement
This study was funded by University of Genova Research Grants (Progetti di Ricerca di Ateneo, PRA) accorded to Valerio Gaetano Vellone MD PhD.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Depatment of Integrated Surgical and Diagnostic Sciences
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵° GYN DMT, a multidisciplinary team of specialist physicians of Ospedale Policlinico San Martino, Genoa, involved in diagnosis and treatment of gynecologic malignancies composed by Serafina Mammoliti (Oncology), Cinzia Caroti (Oncology Clinic), Sergio Costantini (Obstetrics & Gynecology Clinic), Mario Valenzano Menada (Obstetrics & Gynecology Clinic), Melita Moioli (Obstetrics & Gynecology Clinic), Maria Grazia Centurioni (Obstetrics & Gynecology), Franco Alessandri (Obstetrics & Gynecology), Luca Dogliotti (Radiology), Maurizio Cosso (Radiology), Michela Marcenaro (Radiation Oncology), Flavio Giannelli (Radiation Oncology), Stefano Di Domenico (General Surgery) and Franco De Cian (General Surgery).
Data Availability
All the data concerning the presented study, in anonimized form are available to the asking scholars
Abbreviations
- EC
- endometrial carcinoma
- EEC
- endometrioid endometrial carcinoma
- NEEC
- non endometrioid endometrial carcinoma
- TCGA
- Cancer Genome Atlas Research Network
- IHC
- immunohistochemistry
- ER
- estrogen receptor
- PR
- progesterone receptor
- HE
- hematoxylin-eosin stain
- SI
- staining index
- DOD
- dead of disease
- DFS
- disease free survival
- HR
- hazard ratio
- OS
- overall survival
- LVSI
- lymphovascular spaces invasion
- TIL
- tumor infiltrating lymphocytes
